Abstract
BackgroundLung cancer has been considered as one of the most important causes of cancer-related mortality worldwide. To predict lung cancer, researchers identified several molecular markers. However, many underlying markers of lung cancer remain unclear. One of these markers is Rab GDP dissociation inhibitor beta (GDIβ), which is related to tumorigenicity, development and invasion. This study was designed to analyze the biological characteristics of Rab GDIβ and to detect the mRNA and protein expressions of Rab GDIβ in lung cancer cells; this study also aimed to investigate the functions of this protein in lung cancer.MethodUsing online software from the websites of NCBI, ProtParam and so on, we analyzed the biological characteristics of Rab GDIβ. RT-PCR was performed to detect gene expressions in A549 and 16HBE cell lines and immunohistochemistry (IHC) staining was conducted to detect Rab GDIβ protein expression in 57 cases of human lung cancer tissues and 19 cases of normal lung tissues. The association of protein expression with patient clinical and pathological characteristics was assessed in each dataset.ResultsBioinformatic analysis on Rab GDIβ: The mRNA of human Rab GDIβ contains two transcript variants; the common structural elements of the two proteins are mainly α-helix, random coil, β-turn and extended strand. Three and four transmembrane domains could be found in the entire polypeptide chain of protein variants 1 and 2, respectively; both transcript variants are hydrophilic and soluble proteins. The RT-PCR result: The mRNA expression of Rab GDIβ was down-regulation in A549 cells compared with that in 16HBE cells. The IHC result: The protein expression of Rab GDIβ in lung cancer cells was significantly lower than that in normal lung tissues (P <0.05) but was not correlated with patients’ age, gender, tumor size, pathological type, differentiation, lymph node metastasis, distant metastasis and TNM stage.ConclusionThe expression of Rab GDIβ was low in non-small cell lung cancer (NSCLC). Hence, Rab GDIβ may be a tumor suppressor and could function as an indicator of tumorigenesis in NSCLC; nevertheless, this result should be further studied.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_201
Highlights
Lung cancer has been considered as one of the most important causes of cancer-related mortality worldwide
The expression of Rab GDIβ was low in non-small cell lung cancer (NSCLC)
The results showed that the protein level of Rab GDIβ varied with the corresponding mRNA level of Rab GDIβ in Non-small cell lung cancer (NSCLC) and normal tissues; the protein level was not associated with patients’ age, gender, tumor size, pathological type, differentiation, lymph node metastasis, distant metastasis and tumor node metastasis (TNM) stage
Summary
Lung cancer has been considered as one of the most important causes of cancer-related mortality worldwide. Many underlying markers of lung cancer remain unclear. One of these markers is Rab GDP dissociation inhibitor beta (GDIβ), which is related to tumorigenicity, development and invasion. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers Mortality related to this malignant disease has increased by 465% during the last 30 years in People’s Republic of China [2]. Even those NSCLC patients have received standard treatments, including surgical resection, traditional chemotherapy, radiation therapy and molecular targeted therapy, the five-year survival rate of NSCLC is still lower than 15% [3,4,5]. Novel cancer-specific molecular targets and signalling pathways should be developed to establish new therapeutic strategies against this devastating malignancy and to improve patient survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
